ESTIMATION AND VALIDATION FOR DETERMINATION OF ROSUVASTATIN IN HUMAN PLASMA BY LC/MS/MS METHOD

INTRODUCTION Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. Rosuvastatin, chemically it is (3R, 5S, 6E)-7-[4-(4-fluorophenyl)-2-(Nmethylmethanesulfonamido)-6-(propan-2-yl) pyrimidin5-yl]-3, 5-dihydroxyhept-6-enoic acid. The chemical formula is C22H28FN3O6S. The molecular weight is 481.538g/mol. Rosuvastatin is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early ratelimiting step in cholesterol biosynthesis. Decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Rosuvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL). The overall effect is a decrease in plasma LDL and VLDL [1, 2]. Literature surveys reveal few HPLC and LC-MS methods for its determination [3-10]. The simple, accurate, precise and validated method for determination of Rosuvastatin was developed by LC/MS/MS method.